ClinicalTrials.Veeva
Menu

Find clinical trials for Chronic Lymphocytic Leukemia in Charlotte, NC

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

B-Cell Chronic Lymphocytic Leukemia
Leukemia
Lymphoid Leukemia
Lymphoma
B-Cell Lymphoma
Non-Hodgkin Lymphoma
Mantle-Cell Lymphoma

Chronic Lymphocytic Leukemia trials near Charlotte, NC, USA:

A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (MAJIC)

A study of acalabrutinib plus venetoclax (AV) versus venetoclax plus obinutuzumab (VO) in previously untreated chronic lymphocytic ...

Active, not recruiting
Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Drug: Venetoclax
Drug: Obinutuzumab

Phase 3

AstraZeneca
AstraZeneca

Charlotte, North Carolina, United States and 40 other locations

Chronic lymphocytic leukemia (CLL) is the most common leukemia (cancer of blood cells). The purpose of this study...

Enrolling
Chronic Lymphocytic Leukemia (CLL)
Drug: Venetoclax
Drug: Obinutuzumab

Phase 2

AbbVie
AbbVie

Charlotte, North Carolina, United States and 49 other locations

objective of this study is to compare the efficacy of sonrotoclax plus zanubrutinib versus venetoclax plus obinutuzumab in participants with chronic...

Enrolling
CLL
Drug: Zanubrutinib
Drug: Sonrotoclax

Phase 3

BeiGene
BeiGene

Charlotte, North Carolina, United States and 111 other locations

The purpose of this study is to compare the efficacy and safety of pirtobruitinib (LOXO-305) to ibrutinib in participants with CLL/SLL. Participants...

Active, not recruiting
Leukemia, B-cell
Small Lymphocytic Lymphoma
Drug: Pirtobrutinib
Drug: Ibrutinib

Phase 3

Loxo Oncology
Loxo Oncology

Charlotte, North Carolina, United States and 179 other locations

The purpose of this study is to assess progression-free survival (PFS) from treatment with ibrutinib plus venetoclax (I+VEN) compared with obinutuzum...

Active, not recruiting
Leukemia, Lymphocytic, Chronic, B-Cell
Drug: Obinutuzumab
Drug: Venetoclax

Phase 3

Janssen (J&J Innovative Medicine)
Janssen (J&J Innovative Medicine)

Charlotte, North Carolina, United States and 86 other locations

This is a study for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL)...

Active, not recruiting
Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia
Drug: Idelalisib
Drug: Bendamustine

Phase 3

Loxo Oncology
Loxo Oncology

Rock Hill, South Carolina, United States of America and 231 other locations

Status recently updated

The purpose of this study is to compare the efficacy and safety of fixed duration pirtobruitinib (LOXO-305) with VR (Arm A) compared to VR alone (Arm...

Enrolling
Active, not recruiting
Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia
Drug: Venetoclax
Drug: Rituximab

Phase 3

Loxo Oncology
Loxo Oncology

Charlotte, North Carolina, United States and 216 other locations

Follicular Lymphoma is a slow-growing type of non-Hodgkin lymphoma. Chronic lymphocytic leukemia (CLL) is the most common ...

Enrolling
Chronic Lymphocytic Leukemia
Follicular Lymphoma
Drug: ABBV-319

Phase 1

AbbVie
AbbVie

Charlotte, North Carolina, United States and 13 other locations

The purpose of this study is to evaluate the efficacy and safety of acalabrutinib in combination with venetoclax and acalabrutinib in combination wit...

Active, not recruiting
Chronic Lymphocytic Leukemia
Drug: Venetoclax
Drug: Obinutuzumab

Phase 3

Acerta Pharma
Acerta Pharma

Charlotte, North Carolina, United States and 170 other locations

Locations recently updated

B-cell malignancies are a group of cancers of B lymphocytes, a type of white blood cell responsible for fighting infections. The purpose of ...

Enrolling
Chronic Lymphocytic Leukemia
Non-Hodgkin's Lymphoma
Drug: ABBV-525

Phase 1

AbbVie
AbbVie

Charlotte, North Carolina, United States and 28 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems